The stock of Madrigal Pharmaceuticals Inc (MDGL) has gone up by 20.45% for the week, with a 16.90% rise in the past month and a -11.21% drop in the past quarter. The volatility ratio for the week is 2.89%, and the volatility levels for the past 30 days are 3.06% for MDGL. The simple moving average for the last 20 days is 14.48% for MDGL’s stock, with a simple moving average of 1.67% for the last 200 days.
Is It Worth Investing in Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) Right Now?
MDGL has 36-month beta value of -0.45. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MDGL is 18.07M, and currently, short sellers hold a 22.42% ratio of that float. The average trading volume of MDGL on October 31, 2024 was 276.12K shares.
MDGL) stock’s latest price update
The stock price of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has jumped by 13.23 compared to previous close of 215.93. Despite this, the company has seen a gain of 20.45% in its stock price over the last five trading days. zacks.com reported 2024-10-31 that Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consensus Estimate of a loss of $6.94. This compares to loss of $5.34 per share a year ago.
Analysts’ Opinion of MDGL
Wolfe Research, on the other hand, stated in their research note that they expect to see MDGL reach a price target of $382. The rating they have provided for MDGL stocks is “Outperform” according to the report published on June 11th, 2024.
BofA Securities gave a rating of “Underperform” to MDGL, setting the target price at $150 in the report published on April 22nd of the current year.
MDGL Trading at 8.28% from the 50-Day Moving Average
After a stumble in the market that brought MDGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.49% of loss for the given period.
Volatility was left at 3.06%, however, over the last 30 days, the volatility rate increased by 2.89%, as shares surge +18.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.33% lower at present.
During the last 5 trading sessions, MDGL rose by +20.73%, which changed the moving average for the period of 200-days by +2.13% in comparison to the 20-day moving average, which settled at $213.61. In addition, Madrigal Pharmaceuticals Inc saw 5.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MDGL starting from Sibold William John, who sale 6,363 shares at the price of $243.83 back on Sep 09 ’24. After this action, Sibold William John now owns 55,887 shares of Madrigal Pharmaceuticals Inc, valued at $1,551,490 using the latest closing price.
William John Sibold, the Officer of Madrigal Pharmaceuticals Inc, proposed sale 6,363 shares at $243.83 during a trade that took place back on Sep 09 ’24, which means that William John Sibold is holding shares at $1,551,514 based on the most recent closing price.
Stock Fundamentals for MDGL
Current profitability levels for the company are sitting at:
- -34.42 for the present operating margin
- 0.91 for the gross margin
The net margin for Madrigal Pharmaceuticals Inc stands at -33.13. The total capital return value is set at -0.54. Equity return is now at value -106.27, with -72.80 for asset returns.
Based on Madrigal Pharmaceuticals Inc (MDGL), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -3.83. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is -66.61.
Currently, EBITDA for the company is -379.97 million with net debt to EBITDA at 0.72. When we switch over and look at the enterprise to sales, we see a ratio of 321.18. The receivables turnover for the company is 2.23for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.72.
Conclusion
To put it simply, Madrigal Pharmaceuticals Inc (MDGL) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
